| Chemotherapy‐induced peripheral neurotoxicity: a critical analysis SB Park, D Goldstein, AV Krishnan, CSY Lin, ML Friedlander, J Cassidy, ... CA: a cancer journal for clinicians 63 (6), 419-437, 2013 | 799 | 2013 |
| Bell's palsy: aetiology, clinical features and multidisciplinary care TJ Eviston, GR Croxson, PGE Kennedy, T Hadlock, AV Krishnan Journal of Neurology, Neurosurgery & Psychiatry 86 (12), 1356-1361, 2015 | 463 | 2015 |
| Riluzole, neuroprotection and amyotrophic lateral sclerosis BC Cheah, S Vucic, AV Krishnan, MC Kiernan Current medicinal chemistry 17 (18), 1942-1959, 2010 | 327 | 2010 |
| Uremic neuropathy: clinical features and new pathophysiological insights AV Krishnan, MC Kiernan Muscle & Nerve: Official Journal of the American Association of …, 2007 | 285 | 2007 |
| Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies SB Park, AV Krishnan, C Lin, D Goldstein, M Friedlander, MC Kiernan Current medicinal chemistry 15 (29), 3081-3094, 2008 | 270 | 2008 |
| Oxaliplatin‐induced neurotoxicity and the development of neuropathy AV Krishnan, D Goldstein, M Friedlander, MC Kiernan Muscle & Nerve: Official Journal of the American Association of …, 2005 | 267 | 2005 |
| Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy SB Park, CSY Lin, AV Krishnan, D Goldstein, ML Friedlander, MC Kiernan Brain 132 (10), 2712-2723, 2009 | 255 | 2009 |
| Neurological complications in chronic kidney disease R Arnold, T Issar, AV Krishnan, BA Pussell JRSM cardiovascular disease 5, 2048004016677687, 2016 | 233 | 2016 |
| Long‐term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility SB Park, CSY Lin, AV Krishnan, D Goldstein, ML Friedlander, MC Kiernan The oncologist 16 (5), 708-716, 2011 | 228 | 2011 |
| Neurological complications of chronic kidney disease AV Krishnan, MC Kiernan Nature Reviews Neurology 5 (10), 542-551, 2009 | 218 | 2009 |
| Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity SB Park, D Goldstein, CSY Lin, AV Krishnan, ML Friedlander, MC Kiernan Journal of clinical Oncology 27 (8), 1243-1249, 2009 | 217 | 2009 |
| Axonal ion channels from bench to bedside: a translational neuroscience perspective AV Krishnan, CSY Lin, SB Park, MC Kiernan Progress in neurobiology 89 (3), 288-313, 2009 | 194 | 2009 |
| Altered motor nerve excitability in end-stage kidney disease AV Krishnan, RKS Phoon, BA Pussell, JA Charlesworth, H Bostock, ... Brain 128 (9), 2164-2174, 2005 | 181 | 2005 |
| Altered nerve excitability properties in established diabetic neuropathy AV Krishnan, MC Kiernan Brain 128 (5), 1178-1187, 2005 | 171 | 2005 |
| Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis S Vucic, CSY Lin, BC Cheah, J Murray, P Menon, AV Krishnan, ... Brain 136 (5), 1361-1370, 2013 | 154 | 2013 |
| Differentiating lower motor neuron syndromes N Garg, SB Park, S Vucic, C Yiannikas, J Spies, J Howells, W Huynh, ... Journal of Neurology, Neurosurgery & Psychiatry 88 (6), 474-483, 2017 | 132 | 2017 |
| Effect of oxygen stoichiometry on the electrical properties of electrodes S Madhukar, S Aggarwal, AM Dhote, R Ramesh, A Krishnan, D Keeble, ... Journal of applied physics 81 (8), 3543-3547, 1997 | 128 | 1997 |
| Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy AV Krishnan, CSY Lin, MC Kiernan Brain 131 (5), 1209-1216, 2008 | 114 | 2008 |
| Oxaliplatin and axonal Na+ channel function in vivo AV Krishnan, D Goldstein, M Friedlander, MC Kiernan Clinical cancer research 12 (15), 4481-4484, 2006 | 107 | 2006 |
| Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity SB Park, CSY Lin, AV Krishnan, D Goldstein, ML Friedlander, MC Kiernan PloS one 6 (4), e18469, 2011 | 106 | 2011 |
